VTE-prevention for HF, Study of the Efficacy and Safety of 2.5 mg Administered Once Daily for 14 Days

Trial Profile

VTE-prevention for HF, Study of the Efficacy and Safety of 2.5 mg Administered Once Daily for 14 Days

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Jan 2006 to Feb 2006 as reported by ClinicalTrials.gov
    • 12 Jun 2007 Status changed from recruiting to completed.
    • 30 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top